View in EDS

On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.

Saved in:
Bibliographic Details
Title: On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.
Authors: Kayani M; UCL Cancer Institute, University College London, London, UK; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK; Department of Oncology, University College London Hospitals, London, UK., Murphy L; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Dutey-Magni P; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Howlett S; UCL Cancer Institute, University College London, London, UK; Department of Oncology, University College London Hospitals, London, UK., Sachdeva A; Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Surgery, Christie NHS Foundation Trust, Manchester, UK., Padden-Modi M; Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK., Abdel-Aty H; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK; Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK., Brown LC; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Amos CL; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Chan K; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Gilbert DC; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Langley RE; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Brown M; Division of Cancer Sciences, University of Manchester, Manchester, UK., Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Parker CC; Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK., Cross W; St James's University Hospital, Leeds, UK., Malik Z; Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK., Varughese M; Royal Devon University Healthcare NHS Foundation Trust and University of Exeter, UK., Turco F; Institute of Oncology of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland and Faculty of Biosciences, University of Southern Switzerland, Lugano, Switzerland., Millman R; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Matheson D; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., Gillessen S; Institute of Oncology of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland and Faculty of Biosciences, University of Southern Switzerland, Lugano, Switzerland., Clarke NW; Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Surgery, Christie NHS Foundation Trust, Manchester, UK; Department of Urology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester, UK., Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK., James ND; Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK., Attard G; UCL Cancer Institute, University College London, London, UK; Department of Oncology, University College London Hospitals, London, UK. Electronic address: g.attard@ucl.ac.uk.
Corporate Authors: STAMPEDE Collaborators
Source: The Lancet. Oncology [Lancet Oncol] 2026 May; Vol. 27 (5), pp. 625-636.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42061373
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kayani+M%22">Kayani M</searchLink>; UCL Cancer Institute, University College London, London, UK; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK; Department of Oncology, University College London Hospitals, London, UK.<br /><searchLink fieldCode="AU" term="%22Murphy+L%22">Murphy L</searchLink>; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Dutey-Magni+P%22">Dutey-Magni P</searchLink>; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Howlett+S%22">Howlett S</searchLink>; UCL Cancer Institute, University College London, London, UK; Department of Oncology, University College London Hospitals, London, UK.<br /><searchLink fieldCode="AU" term="%22Sachdeva+A%22">Sachdeva A</searchLink>; Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Surgery, Christie NHS Foundation Trust, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Padden-Modi+M%22">Padden-Modi M</searchLink>; Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.<br /><searchLink fieldCode="AU" term="%22Abdel-Aty+H%22">Abdel-Aty H</searchLink>; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK; Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.<br /><searchLink fieldCode="AU" term="%22Brown+LC%22">Brown LC</searchLink>; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Amos+CL%22">Amos CL</searchLink>; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Chan+K%22">Chan K</searchLink>; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Gilbert+DC%22">Gilbert DC</searchLink>; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Langley+RE%22">Langley RE</searchLink>; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Brown+M%22">Brown M</searchLink>; Division of Cancer Sciences, University of Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Sydes+MR%22">Sydes MR</searchLink>; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Parker+CC%22">Parker CC</searchLink>; Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.<br /><searchLink fieldCode="AU" term="%22Cross+W%22">Cross W</searchLink>; St James's University Hospital, Leeds, UK.<br /><searchLink fieldCode="AU" term="%22Malik+Z%22">Malik Z</searchLink>; Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK.<br /><searchLink fieldCode="AU" term="%22Varughese+M%22">Varughese M</searchLink>; Royal Devon University Healthcare NHS Foundation Trust and University of Exeter, UK.<br /><searchLink fieldCode="AU" term="%22Turco+F%22">Turco F</searchLink>; Institute of Oncology of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland and Faculty of Biosciences, University of Southern Switzerland, Lugano, Switzerland.<br /><searchLink fieldCode="AU" term="%22Millman+R%22">Millman R</searchLink>; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Matheson+D%22">Matheson D</searchLink>; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Gillessen+S%22">Gillessen S</searchLink>; Institute of Oncology of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland and Faculty of Biosciences, University of Southern Switzerland, Lugano, Switzerland.<br /><searchLink fieldCode="AU" term="%22Clarke+NW%22">Clarke NW</searchLink>; Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Surgery, Christie NHS Foundation Trust, Manchester, UK; Department of Urology, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Parmar+MKB%22">Parmar MKB</searchLink>; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22James+ND%22">James ND</searchLink>; Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.<br /><searchLink fieldCode="AU" term="%22Attard+G%22">Attard G</searchLink>; UCL Cancer Institute, University College London, London, UK; Department of Oncology, University College London Hospitals, London, UK. Electronic address: g.attard@ucl.ac.uk.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22STAMPEDE+Collaborators%22">STAMPEDE Collaborators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2026 May; Vol. 27 (5), pp. 625-636.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42061373
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(26)00066-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 625
    Titles:
      – TitleFull: On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kayani M
      – PersonEntity:
          Name:
            NameFull: Murphy L
      – PersonEntity:
          Name:
            NameFull: Dutey-Magni P
      – PersonEntity:
          Name:
            NameFull: Howlett S
      – PersonEntity:
          Name:
            NameFull: Sachdeva A
      – PersonEntity:
          Name:
            NameFull: Padden-Modi M
      – PersonEntity:
          Name:
            NameFull: Abdel-Aty H
      – PersonEntity:
          Name:
            NameFull: Brown LC
      – PersonEntity:
          Name:
            NameFull: Amos CL
      – PersonEntity:
          Name:
            NameFull: Chan K
      – PersonEntity:
          Name:
            NameFull: Gilbert DC
      – PersonEntity:
          Name:
            NameFull: Langley RE
      – PersonEntity:
          Name:
            NameFull: Brown M
      – PersonEntity:
          Name:
            NameFull: Sydes MR
      – PersonEntity:
          Name:
            NameFull: Parker CC
      – PersonEntity:
          Name:
            NameFull: Cross W
      – PersonEntity:
          Name:
            NameFull: Malik Z
      – PersonEntity:
          Name:
            NameFull: Varughese M
      – PersonEntity:
          Name:
            NameFull: Turco F
      – PersonEntity:
          Name:
            NameFull: Millman R
      – PersonEntity:
          Name:
            NameFull: Matheson D
      – PersonEntity:
          Name:
            NameFull: Gillessen S
      – PersonEntity:
          Name:
            NameFull: Clarke NW
      – PersonEntity:
          Name:
            NameFull: Parmar MKB
      – PersonEntity:
          Name:
            NameFull: James ND
      – PersonEntity:
          Name:
            NameFull: Attard G
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2026 May
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1